Literature DB >> 8557066

The effect of recombinant human IGF-I on protein metabolism in post-operative patients without nutrition compared to effects in experimental animals.

R Sandström1, E Svanberg, A Hyltander, E Haglind, C Ohlsson, H Zachrisson, B Berglund, E Lindholm, H Brevinge, K Lundholm.   

Abstract

This study has evaluated the effects of recombinant human insulin-like growth factor I (rhIGF-I) to moderately stressed post-operative patients provided with dextrose as the only exogeneous substrate. Thirty patients who underwent elective colorectal surgery were randomized to receive either rhIGF-I (80 micrograms kg-1 bw) subcutaneously twice daily or placebo injections in a double-blind parallel group design. Nitrogen balance, urinary 3-methyl-histidine excretion plasma growth hormone (GH), serum cortisol, IGF-I binding proteins (IGFBP-1,3), glomerular filtration rate, plasma amino acid concentrations and whole-body energy expenditures were measured as effector variables during days 1-5 post-operatively. Animal and isolated tissue experiments were performed as additional control experiments to confirm cellular effectiveness of the recombinant material. rhIGF-I increased significantly the glomerular filtration rate and prevented the adaptive decrease in whole-body energy expenditure in response to partial starvation in the postoperative period. Serum and plasma concentrations of IGFBP-1,3 cortisol, blood glucose and amino acids were not significantly influenced by rhIGF-I administration, while plasma GH levels decreased significantly as expected. rhIGF-I had no effect on either nitrogen balance or protein breakdown (3-methylhistidine excretion) in post-operative patients on dextrose supplementation only, although plasma concentrations of IGF-I increased from 130-140 ng mL-1 to a range of 300-450 ng mL-1. In contrast, IGF-I stimulated the synthesis of both globular and myofibrillar proteins (+50%, P < 0.01), when given as a single dose (100 micrograms kg-1) 2 h before measurements of protein synthesis in skeletal muscles of overnight fasted adult mice. This stimulatory effect by IGF-I (1 microgram mL-1) was also confirmed by measurements of skeletal muscle protein synthesis in vitro (+40%, P < 0.05). Orally re-fed mice had a normal transcription of IGF-I mRNA in skeletal muscle cells, while overnight fasted mice showed a trend to down-regulated transcription. Our results demonstrate that rhIGF-I has several significant physiological effects, without major side-effects, when supplied to partially starved patients in the post-operative phase. The lack of a whole-body nitrogen sparing effect by rhIGF-I alone to post-operative patients is not clear, but was most likely explained by subnormal plasma concentrations of amino acids.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8557066     DOI: 10.1111/j.1365-2362.1995.tb01958.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  4 in total

1.  Effects of human recombinant growth hormone (rhGH) on inflammatory responses in patients undergoing abdominal aortic aneurysm repair.

Authors:  K Mealy; M Barry; L O'Mahony; S Sheehan; P Burke; C McCormack; A S Whitehead; D Bouchier-Hayes
Journal:  Intensive Care Med       Date:  1998-02       Impact factor: 17.440

2.  Initiation of muscle protein synthesis was unrelated to simultaneously upregulated local production of IGF-1 by amino acids in non-proliferating L6 muscle cells.

Authors:  Britt-Marie Iresjö; Lisa Diep; Kent Lundholm
Journal:  PLoS One       Date:  2022-07-08       Impact factor: 3.752

3.  Effects of growth hormone and insulin-like growth factor-1 on postoperative muscle and substrate metabolism.

Authors:  Folke Hammarqvist; Ingmar Wennström; Jan Wernerman
Journal:  J Nutr Metab       Date:  2009-11-22

4.  Liver-derived endocrine IGF-I is not critical for activation of skeletal muscle protein synthesis following oral feeding.

Authors:  Britt-Marie Iresjö; Johan Svensson; Claes Ohlsson; Kent Lundholm
Journal:  BMC Physiol       Date:  2013-05-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.